milnacipran has been researched along with mirtazapine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Pinder, RM | 1 |
| Aguglia, E; Amore, M; Delgado, PL; Gastpar, M; Hawley, C; Hirschfeld, RM; Kasper, S; Linden, M; Massana, J; Mendlewicz, J; Möller, HJ; Montgomery, SA; Nemeroff, CB; Saiz, J; Such, P; Torta, R; Versiani, M | 1 |
| Bouvard, M; Rénéric, JP; Stinus, L | 1 |
| Burrows, GD; Gupta, RK; Tiller, JW | 1 |
| Almási, J; Rihmer, Z | 1 |
| Dubarek, W; Kucia, K | 1 |
| Bellodi, L; Calati, R; Chiesa, A; De Ronchi, D; Perna, G; Serretti, A | 1 |
| Imanishi, T; Koyama, T; Yamauchi, M | 1 |
| Abe, M; Mori, Y; Nakata, S; Ochi, S; Ueno, S; Yamazaki, K; Yoshino, Y | 1 |
| Iga, JI; Nakata, S; Ochi, S; Ueno, SI; Yamazaki, K; Yoshino, Y | 1 |
| Akimoto, H; Asai, S; Hayakawa, T; Minagawa, K; Nagashima, T; Takahashi, Y | 1 |
| Funahashi, H; Haruta-Tsukamoto, A; Hirano, Y; Ishida, Y; Kanemaru-Kawazoe, A; Kogoh, Y; Miyahara, Y; Nishimori, T | 1 |
6 review(s) available for milnacipran and mirtazapine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.
Topics: Antidepressive Agents; Congresses as Topic; Cyclopropanes; Decision Trees; Depressive Disorder; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Lithium; Mianserin; Milnacipran; Mirtazapine; Morpholines; Practice Patterns, Physicians'; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2002 |
Dual action antidepressants and some important considerations.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Second-Generation; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Histamine H1 Antagonists; Humans; Mianserin; Milnacipran; Mirtazapine; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological; Venlafaxine Hydrochloride; Weight Gain | 2003 |
[Review of antidepressants from the TCAs to the third generation drugs].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Drug Combinations; Duloxetine Hydrochloride; Humans; Mianserin; Milnacipran; Mirtazapine; Monoamine Oxidase Inhibitors; Morpholines; Piperazines; Pyrimidines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Trazodone; Triazoles; Venlafaxine Hydrochloride | 2004 |
[Applications and safety of modern antidepressants in patients with liver diseases].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Cyclopropanes; Depressive Disorder; Humans; Liver Diseases; Mianserin; Milnacipran; Mirtazapine; Monoamine Oxidase Inhibitors; Piperazines; Risk Factors; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 2007 |
Novel antidepressants and panic disorder: evidence beyond current guidelines.
Topics: Antidepressive Agents; Clinical Trials as Topic; Cyclopropanes; Duloxetine Hydrochloride; Humans; Mianserin; Milnacipran; Mirtazapine; Morpholines; Panic Disorder; Practice Guidelines as Topic; Reboxetine; Thiophenes | 2011 |
9 other study(ies) available for milnacipran and mirtazapine
| Article | Year |
|---|---|
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Designing a new generation of antidepressant drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Cyclopropanes; Drug Design; Duloxetine Hydrochloride; Humans; Mianserin; Milnacipran; Mirtazapine; Monoamine Oxidase Inhibitors; Rats; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Thiophenes; Venlafaxine Hydrochloride | 1997 |
In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Clonidine; Cyclopropanes; Depression; Desipramine; Dose-Response Relationship, Drug; Drug Synergism; Fluoxetine; Male; Mianserin; Milnacipran; Mirtazapine; Motor Activity; Norepinephrine; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Selective Serotonin Reuptake Inhibitors; Swimming | 2002 |
A combination of mirtazapine and milnacipran augments the extracellular levels of monoamines in the rat brain.
Topics: Animals; Brain; Cyclopropanes; Dopamine; Drug Combinations; Extracellular Fluid; Male; Mianserin; Microdialysis; Milnacipran; Mirtazapine; Norepinephrine; Rats; Rats, Wistar; Serotonin | 2012 |
Antidepressant action via the nitric oxide system: A pilot study in an acute depressive model induced by arginin.
Topics: Acute Disease; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Arginine; Cyclopropanes; Depression; Fluoxetine; Male; Mianserin; Milnacipran; Mirtazapine; Nitric Oxide; Nitric Oxide Synthase; Pilot Projects; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2015 |
Endothelial nitric oxide synthase in rat brain is downregulated by sub-chronic antidepressant treatment.
Topics: Animals; Antidepressive Agents; Brain; Cyclopropanes; Depressive Disorder, Major; Down-Regulation; Drug Administration Schedule; Male; Mianserin; Milnacipran; Mirtazapine; Nitric Oxide; Nitric Oxide Synthase Type III; Rats; Rats, Wistar; RNA, Messenger | 2017 |
Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies.
Topics: Antidepressive Agents; Cohort Studies; Fluvoxamine; Humans; Hyponatremia; Milnacipran; Mirtazapine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sodium | 2022 |
Differential Contribution of 5-HT
Topics: Animals; Antidepressive Agents; Histamine; Mice; Milnacipran; Mirtazapine; Norepinephrine; Serotonin | 2023 |